34 / 38
Neratinib in Advanced NSCLC
Sequist, J Clin Oncol 2010
•
Neratinib (HKI-272) is an
irreversible pan-HER
inhibitor
•
N = 91 patients with
EGFR
mutations and one prior 1
st
generation EGFR TKI for at least 12 weeks
•
3 best
responses
(by far) in
patients with
EGFR
exon
18 mutations